OncoMatch/Clinical Trials/NCT06276283
DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)
Is NCT06276283 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies DZD9008 plus Bevacizumab for non-small cell lung cancer.
Treatment: DZD9008 plus Bevacizumab — This study tests a combination therapy (i.e., DZD9008 plus bevacizumab) in patients with advanced NSCLC harboring EGFR mutations who have progressed on or after standard of care, which aims to understand whether the combination therapy is safe, how well the combination therapy works, and how the body will process DZD9008 when used in combination with bevacizumab.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR mutation
Written documentation of EGFR mutations from an accredited local laboratory: Part A is not limited to a specific EGFR mutation, and Part B only includes patients with EGFR Exon20ins.
Required: EGFR Exon20ins
Part B only includes patients with EGFR Exon20ins.
Excluded: EGFR Exon19del
Concurrent EGFR mutations with approved EGFR-TKIs (e.g., Exon19del, L858R, T790M, G718X, S768I and L861Q; only applicable to Part B).
Excluded: EGFR L858R
Concurrent EGFR mutations with approved EGFR-TKIs (e.g., Exon19del, L858R, T790M, G718X, S768I and L861Q; only applicable to Part B).
Excluded: EGFR T790M
Concurrent EGFR mutations with approved EGFR-TKIs (e.g., Exon19del, L858R, T790M, G718X, S768I and L861Q; only applicable to Part B).
Excluded: EGFR G718X
Concurrent EGFR mutations with approved EGFR-TKIs (e.g., Exon19del, L858R, T790M, G718X, S768I and L861Q; only applicable to Part B).
Excluded: EGFR S768I
Concurrent EGFR mutations with approved EGFR-TKIs (e.g., Exon19del, L858R, T790M, G718X, S768I and L861Q; only applicable to Part B).
Excluded: EGFR L861Q
Concurrent EGFR mutations with approved EGFR-TKIs (e.g., Exon19del, L858R, T790M, G718X, S768I and L861Q; only applicable to Part B).
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: EGFR Exon20ins inhibitor (poziotinib, mobocertinib, CLN-081, BDTX-189, aumolertinib, AP-L1898)
Exception: only applicable to Part B
Treatment with poziotinib, mobocertinib (TAK788), CLN-081, BDTX-189, aumolertinib, AP-L1898, and other EGFR Exon20ins inhibitors prior to the first dose of study drug (only applicable to Part B).
Cannot have received: EGFR tyrosine kinase inhibitor (gefitinib, erlotinib, icotinib, osimertinib, afatinib, dacomitinib, ametinib)
Exception: only applicable to Part B and only if patient had an objective response (PR or CR)
Prior treatment with 1st to 3rd generation EGFR-TKIs (e.g., gefitinib, erlotinib, icotinib, osimertinib, afatinib, dacomitinib, and ametinib) and have had an objective response (i.e., PR and CR) (only applicable to Part B).
Cannot have received: systemic therapy
Exception: only applicable to treatment naïve patients in Part B
Prior systemic treatment for locally advanced or metastatic NSCLC (only applicable to treatment naïve patients in Part B)
Cannot have received: EGFR antibody
Exception: within 4 weeks of first dose
Treatment with EGFR, HER2, or VEGFR antibody within 4 weeks of the first dose of study drug.
Cannot have received: HER2 antibody
Exception: within 4 weeks of first dose
Treatment with EGFR, HER2, or VEGFR antibody within 4 weeks of the first dose of study drug.
Cannot have received: VEGFR antibody
Exception: within 4 weeks of first dose
Treatment with EGFR, HER2, or VEGFR antibody within 4 weeks of the first dose of study drug.
Cannot have received: chemotherapy
Exception: within 2 weeks of first dose
Chemotherapy or other anti-tumor therapies within 2 weeks of the first dose of study drug.
Cannot have received: radiotherapy
Exception: within 14 days of first dose or unresolved radiotherapy-related toxicities
Radiotherapy within 14 days of the first dose of study drug or unresolved radiotherapy-related toxicities.
Cannot have received: investigational drug
Exception: within 5 half-lives of the compound
Treatment with an investigational drug within 5 half-lives of the compound.
Lab requirements
Blood counts
Absolute neutrophil count < 1.5 × 10^9/L; Platelet count < 100 ×10^9/L; Hemoglobin < 9 g/dL
Kidney function
Creatinine ≥1.5 × ULN or creatinine clearance <50 mL/min (measured or calculated by Cockcroft and Gault equation)
Liver function
Total bilirubin >1.5 × ULN if no liver metastases or >3 × ULN in the presence of documented Gilbert's Syndrome or liver metastases; ALT and AST >2.5 × ULN if no demonstrable liver metastases or >5 × ULN in the presence of liver metastases.
Cardiac function
Mean resting corrected QT interval (QTcF) > 470 msec; significant ECG abnormalities; factors that can lead to QTcF prolongation or arrhythmia; evidence of atrial fibrillation (except for drug-related atrial fibrillation that has been resolved after drug discontinuation); evidence of myocardial infarction, congestive heart failure (NYHA Class II or above), and uncontrolled arrhythmia with medication within 6 months of the first dose of study drug.
Inadequate bone marrow reserve or organ function: Absolute neutrophil count < 1.5 × 10^9/L; Platelet count < 100 ×10^9/L; Hemoglobin < 9 g/dL; Total bilirubin >1.5 × ULN if no liver metastases or >3 × ULN in the presence of documented Gilbert's Syndrome or liver metastases; ALT and AST >2.5 × ULN if no demonstrable liver metastases or >5 × ULN in the presence of liver metastases. Creatinine ≥1.5 × ULN or creatinine clearance <50 mL/min (measured or calculated by Cockcroft and Gault equation); The international normalized ratio > 1.5 × ULN and activated partial thromboplastin time (APTT) > 1.5 × ULN; Serum lipase > 1.5 × ULN and serum amylase > 1.5 × ULN. Cardiac: see exclusion criteria 9.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify